Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
Portfolio Pulse from
AnaptysBio, Inc. (Nasdaq: ANAB) is set to announce top-line data from its Phase 2b trial of rosnilimab, a PD-1 depleter and agonist, for rheumatoid arthritis on February 12, 2025. The company will host an investor call and webcast to discuss the results.
February 11, 2025 | 10:45 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
AnaptysBio is announcing results from its Phase 2b trial of rosnilimab, which could significantly impact its stock price depending on the trial's outcome. The announcement is scheduled for February 12, 2025.
The announcement of clinical trial results is a critical event for biotech companies like AnaptysBio. Positive results could lead to a stock price increase due to potential future revenue from a successful drug, while negative results could lead to a decrease. The exact impact will depend on the trial outcomes, which are not yet known.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100